201 related articles for article (PubMed ID: 30858500)
1. H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.
Lee MJ; Miller Z; Park JE; Bhattarai D; Lee W; Kim KB
Sci Rep; 2019 Mar; 9(1):4089. PubMed ID: 30858500
[TBL] [Abstract][Full Text] [Related]
2. Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis.
Guan S; Zhao Y; Lu J; Yu Y; Sun W; Mao X; Chen Z; Xu X; Pan J; Sun S; Yang J
Oncotarget; 2016 Nov; 7(46):75914-75925. PubMed ID: 27713150
[TBL] [Abstract][Full Text] [Related]
3. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
4. The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma.
Gu JJ; Hernandez-Ilizaliturri FJ; Kaufman GP; Czuczman NM; Mavis C; Skitzki JJ; Czuczman MS
Br J Haematol; 2013 Sep; 162(5):657-69. PubMed ID: 23826755
[TBL] [Abstract][Full Text] [Related]
5. Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
Lee MJ; Bhattarai D; Yoo J; Miller Z; Park JE; Lee S; Lee W; Driscoll JJ; Kim KB
J Med Chem; 2019 May; 62(9):4444-4455. PubMed ID: 30964987
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.
Baker AF; Hanke NT; Sands BJ; Carbajal L; Anderl JL; Garland LL
J Exp Clin Cancer Res; 2014 Dec; 33(1):111. PubMed ID: 25612802
[TBL] [Abstract][Full Text] [Related]
7. Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.
Barbagallo I; Giallongo C; Volti GL; Distefano A; Camiolo G; Raffaele M; Salerno L; Pittalà V; Sorrenti V; Avola R; Di Rosa M; Vanella L; Di Raimondo F; Tibullo D
Mol Neurobiol; 2019 Feb; 56(2):1451-1460. PubMed ID: 29948946
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib.
Efentakis P; Doerschmann H; Witzler C; Siemer S; Nikolaou PE; Kastritis E; Stauber R; Dimopoulos MA; Wenzel P; Andreadou I; Terpos E
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707866
[TBL] [Abstract][Full Text] [Related]
9. Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib.
Agbana P; Lee MJ; Rychahou P; Kim KB; Bae Y
Pharm Res; 2020 Oct; 37(11):213. PubMed ID: 33025286
[TBL] [Abstract][Full Text] [Related]
10. Polymer micelle formulations of proteasome inhibitor carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines.
Ao L; Reichel D; Hu D; Jeong H; Kim KB; Bae Y; Lee W
J Pharmacol Exp Ther; 2015 Nov; 355(2):168-73. PubMed ID: 26311812
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib reverses pulmonary arterial hypertension.
Wang X; Ibrahim YF; Das D; Zungu-Edmondson M; Shults NV; Suzuki YJ
Cardiovasc Res; 2016 May; 110(2):188-99. PubMed ID: 26952044
[TBL] [Abstract][Full Text] [Related]
12. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.
Gupta SV; Hertlein E; Lu Y; Sass EJ; Lapalombella R; Chen TL; Davis ME; Woyach JA; Lehman A; Jarjoura D; Byrd JC; Lucas DM
Clin Cancer Res; 2013 May; 19(9):2406-19. PubMed ID: 23515408
[TBL] [Abstract][Full Text] [Related]
14. The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5.
Han B; Yao W; Oh YT; Tong JS; Li S; Deng J; Yue P; Khuri FR; Sun SY
Oncotarget; 2015 Jul; 6(19):17532-42. PubMed ID: 26009898
[TBL] [Abstract][Full Text] [Related]
15. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
16. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
17. Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation.
Agbana P; Park JE; Rychahou P; Kim KB; Bae Y
J Pharm Sci; 2024 Mar; 113(3):711-717. PubMed ID: 37673172
[TBL] [Abstract][Full Text] [Related]
18. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.
Tsakiri EN; Terpos E; Papanagnou ED; Kastritis E; Brieudes V; Halabalaki M; Bagratuni T; Florea BI; Overkleeft HS; Scorrano L; Skaltsounis AL; Dimopoulos MA; Trougakos IP
Sci Rep; 2017 Dec; 7(1):17802. PubMed ID: 29259189
[TBL] [Abstract][Full Text] [Related]
19. Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
Hanke NT; Imler E; Marron MT; Seligmann BE; Garland LL; Baker AF
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1317-1327. PubMed ID: 29766327
[TBL] [Abstract][Full Text] [Related]
20. TOP2A expression predicts responsiveness to carfilzomib in myeloma and informs novel combinatorial strategies for enhanced proteasome inhibitor cell killing.
Reale A; Khong T; Mithraprabhu S; Savvidou I; Hocking J; Bergin K; Ramachandran M; Chen M; Dammacco F; Ria R; Silvestris F; Vacca A; Reynolds J; Spencer A
Leuk Lymphoma; 2021 Feb; 62(2):337-347. PubMed ID: 33131357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]